Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 16/20 | 0.50 |
| ▸ | AGPAT2 | O15120 | 3/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095747 | 0.80 | BACE1 (0.54) | PTGER1AGPAT2CYP2C9TBXA2R | |
| SCHEMBL2111464 | 0.78 | PTGER1 (0.55) | PTGER1C5AR1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL2112850 | 0.76 | PTGER1 (0.55) | PTGER1C5AR1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL4882597 | 0.73 | CYP2C9 (0.57) | PTGER1CYP2C9CYP3A4 | |
| SCHEMBL4884388 | 0.71 | PTGER1 (0.63) | PTGER1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL6639567 | 0.71 | MPO (0.49) | CYP3A4 | |
| SCHEMBL1988682 | 0.71 | PTGER1 (0.60) | PTGER1C5AR1CYP2C9TBXA2R | |
| SCHEMBL5096000 | 0.70 | PTGER1 (0.64) | PTGER1CYP2C9CYP3A4TBXA2R | |
| SCHEMBL6430443 | 0.70 | PTGER1 (0.53) | PTGER1CYP2C9 | |
| SCHEMBL11884926 | 0.70 | SLC6A4 (0.54) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | PTGER1 3890/4885AGPAT2 94/4885C5AR1 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.